Sorafenib
Sarcomatoid Renal Cell Carcinoma
National Cancer Institute (NCI)Small moleculePhase 2Dormant
BB
65/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 50/ 100
- Competitive Position
- 89/ 100
Competitive context
10 Active assets in the Sarcomatoid Renal Cell Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Nivolumab City of Hope Medical Center | Phase 3 | BB |
Ipilimumab City of Hope Medical Center | Phase 3 | BB |
Cabozantinib City of Hope Medical Center | Phase 3 | BB |
Pazopanib Mayo Clinic | Phase 2 | B |
Clostridium Butyricum Miyairi 588 City of Hope Medical Center | Phase 2 | B |
View all 16 →
Same molecule, other indications
Sorafenib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →